http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 09 Jun 2026 14:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+List/Buy+this+biotech+stock+now%2C+Mizuho+urges/26623013.html <p>Mizuho has named its top pick for June 2026, reiterating an Outperform rating and $14 price target on the stock as momentum builds around its lead oncology asset, VS-7375.</p><p>Verastem Oncology (NASDAQ: VSTM) is the stock in question. Analyst Graig Suvannavejh cited four factors behind the call, including a "scorching hot RAS inhibitor space," rising interest in the pancreatic ductal adenocarcinoma market, a compelling valuation with shares down 52% year-to-date against a 5% gain for the XBI, and expected data updates this month that Mizuho believes "could help put its competitive positioning in PDAC in a better light." </p><p>Verastem currently trades http://www.streetinsider.com/Hot+List/Buy+this+biotech+stock+now%2C+Mizuho+urges/26623013.html Tue, 09 Jun 2026 14:00:00 -0400 VSTM http://www.streetinsider.com/Hot+List+Pro/Buy+this+biotech+stock+now%2C+Mizuho+urges/26623013.html <p>Mizuho has named its top pick for June 2026, reiterating an Outperform rating and $14 price target on the stock as momentum builds around its lead oncology asset, VS-7375.</p><p>Verastem Oncology (NASDAQ: VSTM) is the stock in question. Analyst Graig Suvannavejh cited four factors behind the call, including a "scorching hot RAS inhibitor space," rising interest in the pancreatic ductal adenocarcinoma market, a compelling valuation with shares down 52% year-to-date against a 5% gain for the XBI, and expected data updates this month that Mizuho believes "could help put its competitive positioning in PDAC in a better light." </p><p>Verastem currently trades http://www.streetinsider.com/Hot+List+Pro/Buy+this+biotech+stock+now%2C+Mizuho+urges/26623013.html Tue, 09 Jun 2026 14:00:00 -0400 VSTM http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html <p>Verastem Oncology (NASDAQ: VSTM) received Fast Track Designation from the U.S. Food and Drug Administration for VS-7375, an oral investigational drug targeting KRAS G12D mutations in non-small cell lung cancer patients.</p> <p>The designation applies to adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody treatment. The FDA previously granted Fast Track Designation for VS-7375 in pancreatic cancer with the same mutation.</p> <p>VS-7375 is designed as a dual inhibitor that binds both active and inactive states of the KRAS G12D protein. The KRAS G12D mutation occurs in 5% of http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html Wed, 03 Jun 2026 16:01:31 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html <p>Verastem Oncology (NASDAQ: VSTM) received Fast Track Designation from the U.S. Food and Drug Administration for VS-7375, an oral investigational drug targeting KRAS G12D mutations in non-small cell lung cancer patients.</p> <p>The designation applies to adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody treatment. The FDA previously granted Fast Track Designation for VS-7375 in pancreatic cancer with the same mutation.</p> <p>VS-7375 is designed as a dual inhibitor that binds both active and inactive states of the KRAS G12D protein. The KRAS G12D mutation occurs in 5% of http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html Wed, 03 Jun 2026 16:01:31 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html <p>Verastem Oncology (NASDAQ: VSTM) received Fast Track Designation from the U.S. Food and Drug Administration for VS-7375, an oral investigational drug targeting KRAS G12D mutations in non-small cell lung cancer patients.</p> <p>The designation applies to adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody treatment. The FDA previously granted Fast Track Designation for VS-7375 in pancreatic cancer with the same mutation.</p> <p>VS-7375 is designed as a dual inhibitor that binds both active and inactive states of the KRAS G12D protein. The KRAS G12D mutation occurs in 5% of http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html Wed, 03 Jun 2026 16:01:31 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html <p>Verastem Oncology (NASDAQ: VSTM) received Fast Track Designation from the U.S. Food and Drug Administration for VS-7375, an oral investigational drug targeting KRAS G12D mutations in non-small cell lung cancer patients.</p> <p>The designation applies to adult patients with KRAS G12D-mutated unresectable locally advanced or metastatic non-small cell lung cancer who have received platinum-based chemotherapy and an anti-PD-(L)1 antibody treatment. The FDA previously granted Fast Track Designation for VS-7375 in pancreatic cancer with the same mutation.</p> <p>VS-7375 is designed as a dual inhibitor that binds both active and inactive states of the KRAS G12D protein. The KRAS G12D mutation occurs in 5% of http://www.streetinsider.com/FDA/FDA+grants+fast+track+status+to+Verastem%27s+lung+cancer+drug+VS-7375/26598657.html Wed, 03 Jun 2026 16:01:31 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Press+Releases/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html <p class="bwalignc"> <i>Phase 1 TARGET-D 101 dose escalation, dose expansion, and combination clinical trial ongoing with early data updates expected in the first half of 2026 and more mature data expected in the second half of 2026</i> </p><p class="bwalignc"> <i>Phase 2 registration directed, open label TARGET-D 202 clinical trial initiated for 2L/3L advanced non-small cell lung cancer (NSCLC)</i> </p><p class="bwalignc"> <i>FDA Fast Track Designation previously granted for VS-7375 for KRAS G12D-mutated advanced or metastatic pancreatic cancer</i> </p> <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and http://www.streetinsider.com/Business+Wire/Verastem+Oncology+Announces+U.S.+FDA+Fast+Track+Designation+for+VS-7375%2C+an+Oral+and+Potential+Best-in-Class+Investigational+KRAS+G12D+%28ONOFF%29+Inhibitor+for+the+Treatment+of+KRAS+G12D-Mutated+Locally/26598647.html Wed, 03 Jun 2026 16:01:00 -0400 A.06822034 O.12496614 O.20026344 VSTM http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Verastem%2C+Inc.+++++++++++++++++++++++/26576000.html si-local-file:///var/storage/secattach/20260529/26576000.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Verastem%2C+Inc.+++++++++++++++++++++++/26576000.html Fri, 29 May 2026 16:41:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Verastem%2C+Inc.+++++++++++++++++++++++/26576000.html si-local-file:///var/storage/secattach/20260529/26576000.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Verastem%2C+Inc.+++++++++++++++++++++++/26576000.html Fri, 29 May 2026 16:41:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559309.html si-local-file:///var/storage/secattach/20260527/26559309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559309.html Wed, 27 May 2026 17:46:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559309.html si-local-file:///var/storage/secattach/20260527/26559309.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559309.html Wed, 27 May 2026 17:46:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559303.html si-local-file:///var/storage/secattach/20260527/26559303.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559303.html Wed, 27 May 2026 17:44:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559303.html si-local-file:///var/storage/secattach/20260527/26559303.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Verastem%2C+Inc.++++++++++++For%3A+May+21++Filed+by%3A+BAILEY+MICHAEL+P/26559303.html Wed, 27 May 2026 17:44:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26558741.html si-local-file:///var/storage/secattach/20260527/26558741.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26558741.html Wed, 27 May 2026 16:47:00 -0400 O.12496614 VSTM http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26558741.html si-local-file:///var/storage/secattach/20260527/26558741.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Verastem%2C+Inc.+++++++++++++++++++++++++Filed+by%3A+Gagnon+Robert+E./26558741.html Wed, 27 May 2026 16:47:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Present+at+Jefferies+Healthcare+Conference/26553499.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. </p><p> A live webcast of the fireside chat can be accessed under “Events &amp; Presentations” on the Company’s website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.verastem.com&amp;esheet=54541637&amp;newsitemid=20260527590882&amp;lan=en-US&amp;anchor=www.verastem.com&amp;index=1&amp;md5=e8930638c43e31f9818bfdd0e58cc1bc" shape="rect">www.verastem.com</a>. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. </p><p> <b>About Verastem Oncology</b> </p><p> Verastem Oncology (Nasdaq: http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Present+at+Jefferies+Healthcare+Conference/26553499.html Wed, 27 May 2026 07:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Present+at+Jefferies+Healthcare+Conference/26553499.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. </p><p> A live webcast of the fireside chat can be accessed under “Events &amp; Presentations” on the Company’s website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.verastem.com&amp;esheet=54541637&amp;newsitemid=20260527590882&amp;lan=en-US&amp;anchor=www.verastem.com&amp;index=1&amp;md5=e8930638c43e31f9818bfdd0e58cc1bc" shape="rect">www.verastem.com</a>. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. </p><p> <b>About Verastem Oncology</b> </p><p> Verastem Oncology (Nasdaq: http://www.streetinsider.com/Press+Releases/Verastem+Oncology+to+Present+at+Jefferies+Healthcare+Conference/26553499.html Wed, 27 May 2026 07:30:00 -0400 O.12496614 VSTM http://www.streetinsider.com/Business+Wire/Verastem+Oncology+to+Present+at+Jefferies+Healthcare+Conference/26553499.html <p> BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 am ET in New York. </p><p> A live webcast of the fireside chat can be accessed under “Events &amp; Presentations” on the Company’s website at <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.verastem.com&amp;esheet=54541637&amp;newsitemid=20260527590882&amp;lan=en-US&amp;anchor=www.verastem.com&amp;index=1&amp;md5=e8930638c43e31f9818bfdd0e58cc1bc" shape="rect">www.verastem.com</a>. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. </p><p> <b>About Verastem Oncology</b> </p><p> Verastem Oncology (Nasdaq: http://www.streetinsider.com/Business+Wire/Verastem+Oncology+to+Present+at+Jefferies+Healthcare+Conference/26553499.html Wed, 27 May 2026 07:30:00 -0400 O.12496614 VSTM